Jubilant Pharmova Ltd. (JUBLPHARMA) fundamentals
Jubilant Pharmova Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as JUBLPHARMA (ISIN INE700A01033). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Jubilant Pharmova Ltd. does
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Valuation and market data
| Last close | ₹1025.20 |
|---|---|
| Market capitalisation | ₹16,203 crore |
| Enterprise value | ₹20,825 crore |
| P/E (TTM) | 40.76 |
| Price to book | 2.28 |
| Price to sales (TTM) | 1.11 |
| Book value per share | ₹448.94 |
| Dividend yield | 48.77% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jun 16 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹266 crore | ₹29 crore | ₹20 crore | 3.97 |
| Mar 2025 | ₹252 crore | ₹41 crore | ₹22 crore | 1.21 |
| Mar 2024 | ₹888 crore | ₹42 crore | ₹32 crore | 1.99 |
| Mar 2023 | ₹948 crore | ₹79 crore | ₹50 crore | 3.13 |
| Mar 2022 | ₹852 crore | ₹85 crore | ₹80 crore | 5.05 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 47.7% |
|---|---|
| Foreign institutions (FII) | 15.9% |
| Mutual funds | 9.0% |
| Other domestic institutions | 3.4% |
| Retail and others | 24.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.